Modular dCas9 Therapeutics for Precise Gene Expression Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic modalities, such as small molecules and antibodies, are ineffective in treating diseases that require modification at the level of gene expression, and existing CRISPR/Cas9 systems lack specificity and precision for long-lasting gene regulation.
Innovation Solution
A novel platform using modular self-assembling macromolecular machines that integrate CRISPR/dCas9 technologies with RNA-guided molecules and small RNA binding polypeptides to selectively control gene expression at specific genomic loci, minimizing off-target effects and enabling personalized treatment of a wide range of human diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If CRISPR/Cas9 system is used for gene editing, then gene modification capability is improved, but specificity and precision for long-lasting gene regulation deteriorates
Solution Approach 1:
The system divides the gene regulation function into separate modular components: a guide RNA for target recognition, a dead Cas9 (dCas9) protein for positioning, and separate effector domains for specific regulatory actions. This segmentation allows each component to be optimized independently, improving both versatility and precision.
Solution Approach 2:
The patent introduces an intermediary dCas9 protein that cannot cut DNA but serves as a precise positioning platform. This intermediary mediates between the guide RNA (which provides target specificity) and the effector domains (which provide regulatory function), thereby enhancing precision while maintaining versatility.
2Ease of operation
If traditional therapeutic modalities (small molecules and antibodies) are used, then ease of administration is improved, but effectiveness for diseases requiring gene expression modification deteriorates
Solution Approach 1:
The system employs endogenous cellular machinery (RNA polymerase, transcription factors, chromatin remodeling complexes) to carry out gene regulation. The therapeutic components self-assemble and utilize the cell's own processes, eliminating the need for complex external administration while achieving reliable gene expression modification.
3Reliability
If gene expression modulation is achieved, then treatment effectiveness for genetic diseases is improved, but off-target effects increase
Solution Approach 1:
The guide RNA is designed with highly specific sequences that match only the intended target locus. The dCas9-effector complex is delivered in a localized manner (e.g., via AAV vectors targeted to specific tissues), ensuring that gene modulation occurs only at the desired location and minimizing off-target effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This platform allows for precise and personalized modulation of gene expression, effectively treating diseases by activating or repressing target genes associated with specific diseases, offering a revolutionary impact on medicine with broad applicability and high specificity.
Implementation Method 1
a guide RNA (gRNA) that directs a dead Cas9 (dCas9) protein to a target sequence in a genome
Implementation Method 2
an RNA molecule that comprises one or more RNA aptamers and that binds to one or more RNA-binding polypeptides
Data Source
AI summary
Provided in the present disclosure include targeted therapeutics for regulating gene transcription at a specific locus (or loci). Such targeted therapeutics can be used as novel genomic therapeutics for treating and/or preventing a disease or disorder that is tightly associated with the locus where the gene transcription is reprogrammed using the present systems. The regulatory system comprises a macromolecular complex of transcription effector proteins that is directed to a locus using CRISPR-dCas9.